Tout DSpace

Parcourir par sujet "Omalizumab"

Voici les éléments 1-3 de 3

    • Clinical profile of severe asthmatics receiving biological treatment: see behind the scenes 

      Kotsiou O.S., Gourgoulianis K.I., Daniil Z. (2021)
      The clinical phenotyping of severe asthma could improve treatment outcomes, quality of life, morbidity, and mortality of asthma patients. The growing availability of rich clinical data could provide opportunities to address ...

    • Effectiveness of autologous whole-blood injections in patients with refractory chronic spontaneous urticaria 

      Kitsioulis N.A., Xepapadaki P., Roussaki-Schulze A.-V., Papadopoulos N., Zafiriou E. (2017)
      Background: Nonsedating antihistamines are the treatment of choice for chronic spontaneous urticaria (CSU), while omalizumab and immunosuppressants have also been approved as an add-on treatment. Autologous whole-blood ...

    • SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics 

      Papaioannou A.I., Fouka E., Tzanakis N., Antoniou K., Samitas K., Zervas E., Kostikas K., Bartziokas K., Porpodis K., Papakosta D., Tzouvelekis A., Gerogianni I., Kotsiou O., Makris M., Rovina N., Vlachou G., Markatos M., Vittorakis S., Katsoulis K., Papanikolaou I., Afthinos A., Katsaounou P., Steiropoulos P., Latsios D., Dimakou K., Koukidou S., Hillas G., Tryfon S., Kallieri M., Georgopoulou A., Avarlis P., Bakakos P., Markopoulou K., Gaki E., Paspala A., Kyriakaki Z., Gourgoulianis K.I., Papiris S., Loukides S. (2022)
      Background: At the beginning of the pandemic, there have been considerable concerns regarding coronavirus disease 2019 (COVID-19) severity and outcomes in patients with severe asthma treated with biologics. Objective: To ...